Recombinant activated factor VII in a patient with intracranial hemorrhage and severe thrombocytopenia
Abstract Hemorrhage in patients with hematologic malignancies is often difficult to manage as many of these patients also have coagulopathy and thrombocytopenia of varying severity. Recombinant factor VIIa is a FDA‐approved agent for management of bleeding in hemophilia patients with inhibitors. Use...
Guardado en:
Autores principales: | Amir M. Ansari, Adam Khorasanchi, Armaghan Faghihimehr, Amir Toor |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8c32758b797d4d20b4dd364c0121569e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Historical aspects of the problem of surgical treatment of hemorrhagic stroke. The role of intracranial pressure in the choice of treatment tactics (review of literature)
por: S. A. Sevryuk, et al.
Publicado: (2021) -
A new surgical method of treatment spontaneous intracranial hemorrhage
por: Du Ning, et al.
Publicado: (2021) -
Thrombocytopenia as Type 1 ROP Biomarker: A Longitudinal Study
por: Raffaele Parrozzani, et al.
Publicado: (2021) -
THROMBOCYTOPENIA IN CASES OF HELICOBACTER PYLORI INFECTION
por: Nadia Pervez, et al.
Publicado: (2021) -
EDTA‐dependent pseudo thrombocytopenia mimicking dengue fever‐associated persistent thrombocytopenia: A case report
por: Gentle Sunder Shrestha, et al.
Publicado: (2021)